Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Epigenetics interest garners Syndax Pharmaceuticals $26.6m Series B

Authored by Karl Simpson

Epigenetics is an area which is receiving a good deal of interest currently, not only in the area cancer research but also in other therapeutic areas too, such as autoimmune and inflammation. Massachusetts based Syndax Pharmaceuticals develops epigenetic therapies for  treatment-resistant cancers. The company’s lead product is Entinostat, for which it holds the worldwide rights, is an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer. Entinostat has been studied in more than 800 cancer patients where objective tumor responses have been observed in both solid and haematologic malignancies.

This progress has netted the Syndax a series B financing round of $26.6m, with investment coming from Domain Associates, MPM Capital, Forward Ventures, and RMI. The company intends to advance its late-stage pipeline, which will include the beginning of an NDA-enabling Phase III study of entinostat in metastatic breast cancer. In the completed Phase II ENCORE 301 study, entinostat was shown to extend both PFS and OS when added to exemestane in postmenopausal women with estrogen receptor-positive (ER+) metastatic breast cancer whose cancer had cancer had progressed after treatment with a non-steroidal aromatase inhibitor.

Arlene Morris, Syndax’s CEO said “The series B financing enables us to continue to advance entinostat toward registration, where we believe the opportunity in breast cancer and lung cancer alone exceeds $2bn”.

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Head Office
Liftstream Ltd.
111 Buckingham Palace Road,
London,
SW1W 0SR
   Tel: ​+44 (0)20 3180 5880
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap